Acquisition Shire Inc.
TSX : SHQ

Acquisition Shire Inc.

October 21, 2005 18:28 ET

Results of the Special Meeting of the Holders of Exchangeable Shares of Shire Acquisition Inc.

MONTREAL, QUEBEC--(CCNMatthews - Oct. 21, 2005) - Shire Acquisition Inc ("Shire Acquisition") (TSX:SHQ) announces that the holders of its Exchangeable Shares approved the special resolution proposed in the Management Information Circular dated September 12, 2005 , without amendment, at a special meeting held today in Montreal.

The meeting of the holders of Exchangeable Shares of Shire Acquisition was held in connection with the proposed scheme of arrangement between Shire Pharmaceuticals Group plc ("SPG") and its holders of ordinary shares under section 425 of the UK Companies Act 1985 (the "Scheme"), as announced by SPG on September 8, 2005. Upon the Scheme becoming effective, it will result in a new UK listed holding company, Shire plc, being established above SPG.

The Scheme will also result in the Exchangeable Shares of Shire Acquisition being exchanged on a one-for-one basis for new Exchangeable Shares. The new Exchangeable Shares will be convertible into three ordinary shares or one ADS representing three ordinary shares of Shire plc rather than SPG.

Notes to editors

Shire Acquisition Inc.

Shire Acquisition is an indirect wholly owned subsidiary of SPG. The Exchangeable Shares of Shire Acquisition are listed on the Toronto Stock Exchange and are convertible into three ordinary shares of SPG or one ADS representing three ordinary shares of SPG. SPG's ordinary shares are listed on the London Stock Exchange and SPG's ADSs are listed on NASDAQ.

Shire Pharmaceuticals Group plc

SPG is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), renal diseases and human disease therapies. SPG has operations in the world's key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.
For further information, please visit the company's website: www.shire.com.

www.shire.com

Contact Information

  • Acquisition Shire Inc.
    Investor Relations
    Brian Piper (North America)
    (484) 595-8252
    or
    Acquisition Shire Inc.
    Investor Relations
    Clea Rosenfeld (Rest of the World)
    +44 1256 894 160
    or
    Acquisition Shire Inc.
    Media
    Matthew Cabrey (North America)
    (484) 595-8248
    or
    Acquisition Shire Inc.
    Media
    Jessica Mann (Rest of the World)
    +44 1256 894 280